{
    "info": {
        "nct_id": "NCT03021460",
        "official_title": "Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma",
        "inclusion_criteria": "* PRE-REGISTRATION- INCLUSION CRITERIA\n* Diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy\n* At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as >= 1.0 cm with computed tomography [CT] scan, CT component of a positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI]) or at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is >= 1.5 cm when assessed by CT scan)\n\n  * NOTE: tumor lesions in a previously irradiated area are not considered measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Provide informed written consent\n* Patient is willing to undergo treatment and monitoring at the enrolling institution\n* Willing to provide tissue and blood samples for correlative research purposes\n* REGISTRATION- INCLUSION CRITERIA\n* Histologic or cytologic confirmation of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy\n* Only if patient has had previous exposure to anti-PD-1 or anti-PD-L1 therapy:\n\n  * Patient had disease progression on or within 6 months after anti-PD-1/anti-PD-L1 therapy in the metastatic setting OR\n  * Patient had disease progression within 6 months after the last dose of adjuvant/neoadjuvant anti-PD-1/anti-PD-L1 treatment\n* Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)\n* Platelet count >= 75,000/mm^3 (obtained =< 14 days prior to registration)\n\n  * Criteria must be met without a transfusion =< four weeks prior to registration\n* Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)\n* Total bilirubin =< 1.5 X upper limit of normal (ULN); if total bilirubin > 1.5 X ULN then direct bilirubin =< ULN (obtained =< 14 days prior to registration)\n* Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN OR =< 5 X ULN for patients with liver metastases (obtained =< 14 days prior to registration)\n* Creatinine =< 1.5 X ULN and creatinine clearance (CrCL) >= 30 ml/min per Cockcroft Gault formula (obtained =< 14 days prior to registration)\n* Patients of childbearing potential only, negative urine pregnancy test done =< 7 days prior to study registration\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* PRE-REGISTRATION EXCLUSION CRITERIA\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication; adequate contraception is defined as 2 methods of birth control (e.g., hormonal contraceptives, intrauterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide) or prior surgical sterilization, or abstinence from heterosexual activity\n* Prior treatment with ibrutinib or prior exposure to BTK inhibitors\n* Uveal melanoma\n* Current use of warfarin or other vitamin K antagonists\n* Require continuous treatment with a strong CYP3A inhibitor\n* Currently participating or has participated in a study of an investigational cancer therapy agent or using an investigational device within 28 days prior to study registration\n* Live vaccines within 28 days prior to study pre-registration\n* Invasive surgical procedure within 28 days prior to study pre-registration\n* History of clinically severe (e.g., requires chronic immunosuppressive therapy, [e.g., cyclosporine A, tacrolimus]) autoimmune disease (e.g., ulcerative colitis, lupus), or history of organ transplant\n* Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection\n* Gastrointestinal disease that might inhibit ibrutinib absorption (e.g., malabsorption syndrome, resection of the stomach or a large portion of small bowel, or partial/complete bowel obstruction), or unable to swallow capsules\n* Active central nervous system metastases and/or carcinomatous meningitis\n\n  * Note: Patients with untreated brain metastasis will be excluded; patients with previously treated brain metastases may participate provided they meet the following criteria:\n\n    * Inactive (without evidence of progression which is documented by CT or MRI within 90 days prior to registration), AND\n    * On =< 10 mg/day prednisone or equivalent for at least 28 days prior pre-registration\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome within =< 180 days prior to registration, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification\n* Other active malignancy =< 3 years prior to pre-registration; note: if there is a history of prior malignancy, the patient must not be receiving other specific treatment for cancer\n\n  * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix\n* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome =< 6 months prior to pre-randomization\n* Known bleeding disorders (von Willebrand's disease or hemophilia)\n* History of ischemic stroke or intracranial hemorrhage =< 180 days prior to pre-registration\n* Currently active, clinically significant hepatic impairment Child-Pugh class A, B or C according to the Child Pugh classification\n* Unresolved toxicities from prior anti-cancer therapy, defined as not resolved to Common Terminology Criteria for Adverse Events (CTCAE, version [v]4.0) grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria with the exceptions of alopecia and peripheral neuropathy\n* REGISTRATION- EXCLUSION\n* Failure to confirm histologically or cytologically unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy\n* Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody [mAb]) =< 28 days prior to registration\n* Received a strong cytochrome P450 (CYP) 3A inhibitor =< 7 days prior to registration\n* Concurrent systemic immunosuppressant therapy =< 21 days prior to registration\n* Recent infection requiring systemic antibiotic treatment that was completed =< 14 prior to registration",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Provide informed written consent",
            "criterions": [
                {
                    "exact_snippets": "Provide informed written consent",
                    "criterion": "informed written consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN OR =< 5 X ULN for patients with liver metastases (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (aspartate transaminase [AST]) ... =< 2.5 x ULN OR =< 5 X ULN for patients with liver metastases (obtained =< 14 days prior to registration)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for patients with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (alanine transaminase [ALT]) ... =< 2.5 x ULN OR =< 5 X ULN for patients with liver metastases (obtained =< 14 days prior to registration)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for patients with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "ANC laboratory value timing",
                    "requirements": [
                        {
                            "requirement_type": "time from registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient had disease progression within 6 months after the last dose of adjuvant/neoadjuvant anti-PD-1/anti-PD-L1 treatment",
            "criterions": [
                {
                    "exact_snippets": "disease progression within 6 months after the last dose of adjuvant/neoadjuvant anti-PD-1/anti-PD-L1 treatment",
                    "criterion": "disease progression after adjuvant/neoadjuvant anti-PD-1/anti-PD-L1 treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose to progression",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to provide tissue and blood samples for correlative research purposes",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide tissue ... for correlative research purposes",
                    "criterion": "tissue sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing to provide ... blood samples for correlative research purposes",
                    "criterion": "blood sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is willing to undergo treatment and monitoring at the enrolling institution",
            "criterions": [
                {
                    "exact_snippets": "Patient is willing to undergo treatment",
                    "criterion": "willingness to undergo treatment",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to undergo ... monitoring at the enrolling institution",
                    "criterion": "willingness to undergo monitoring at the enrolling institution",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients of childbearing potential only, negative urine pregnancy test done =< 7 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Patients of childbearing potential only",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine pregnancy test done =< 7 days prior to study registration",
                    "criterion": "urine pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to study registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 75,000/mm^3 (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 75,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "platelet count measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Criteria must be met without a transfusion =< four weeks prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Criteria must be met without a transfusion =< four weeks prior to registration",
                    "criterion": "transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last transfusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of unresectable stage III or metastatic melanoma (stage IV)",
                    "criterion": "melanoma stage",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable stage III",
                                "metastatic melanoma (stage IV)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to local therapy",
                    "criterion": "amenability to local therapy",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Only if patient has had previous exposure to anti-PD-1 or anti-PD-L1 therapy:",
            "criterions": [
                {
                    "exact_snippets": "previous exposure to anti-PD-1 or anti-PD-L1 therapy",
                    "criterion": "previous exposure to anti-PD-1 or anti-PD-L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient had disease progression on or within 6 months after anti-PD-1/anti-PD-L1 therapy in the metastatic setting OR",
            "criterions": [
                {
                    "exact_snippets": "disease progression on or within 6 months after anti-PD-1/anti-PD-L1 therapy in the metastatic setting",
                    "criterion": "disease progression after anti-PD-1/anti-PD-L1 therapy in the metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "anti-PD-1",
                                "anti-PD-L1"
                            ]
                        },
                        {
                            "requirement_type": "setting",
                            "expected_value": "metastatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: tumor lesions in a previously irradiated area are not considered measurable disease",
            "criterions": [
                {
                    "exact_snippets": "tumor lesions in a previously irradiated area are not considered measurable disease",
                    "criterion": "tumor lesions in previously irradiated area",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION- INCLUSION CRITERIA",
            "criterions": [
                {
                    "exact_snippets": "PRE-REGISTRATION- INCLUSION CRITERIA",
                    "criterion": "pre-registration inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "hemoglobin laboratory value timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 X upper limit of normal (ULN); if total bilirubin > 1.5 X ULN then direct bilirubin =< ULN (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 X upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if total bilirubin > 1.5 X ULN then direct bilirubin =< ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "laboratory test timing",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologic or cytologic confirmation of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy",
            "criterions": [
                {
                    "exact_snippets": "Histologic or cytologic confirmation",
                    "criterion": "melanoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologic",
                                "cytologic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable stage III or metastatic melanoma (stage IV)",
                    "criterion": "melanoma stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable stage III",
                                "metastatic melanoma (stage IV)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to local therapy",
                    "criterion": "amenability to local therapy",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine =< 1.5 X ULN and creatinine clearance (CrCL) >= 30 ml/min per Cockcroft Gault formula (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine =< 1.5 X ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance (CrCL) >= 30 ml/min per Cockcroft Gault formula (obtained =< 14 days prior to registration)",
                    "criterion": "creatinine clearance (CrCL)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft Gault formula"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Unresolved toxicities from prior anti-cancer therapy, defined as not resolved to Common Terminology Criteria for Adverse Events (CTCAE, version [v]4.0) grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria with the exceptions of alopecia and peripheral neuropathy",
            "criterions": [
                {
                    "exact_snippets": "Unresolved toxicities from prior anti-cancer therapy, defined as not resolved to Common Terminology Criteria for Adverse Events (CTCAE, version [v]4.0) grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria",
                    "criterion": "toxicities from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": "resolved to CTCAE v4.0 grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exceptions of alopecia and peripheral neuropathy",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception to toxicity resolution requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exceptions of alopecia and peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "exception to toxicity resolution requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inactive (without evidence of progression which is documented by CT or MRI within 90 days prior to registration), AND",
            "criterions": [
                {
                    "exact_snippets": "Inactive (without evidence of progression which is documented by CT or MRI within 90 days prior to registration)",
                    "criterion": "disease activity",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "inactive"
                        },
                        {
                            "requirement_type": "evidence of progression",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "documentation method",
                            "expected_value": [
                                "CT",
                                "MRI"
                            ]
                        },
                        {
                            "requirement_type": "documentation time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of clinically severe (e.g., requires chronic immunosuppressive therapy, [e.g., cyclosporine A, tacrolimus]) autoimmune disease (e.g., ulcerative colitis, lupus), or history of organ transplant",
            "criterions": [
                {
                    "exact_snippets": "History of clinically severe ... autoimmune disease (e.g., ulcerative colitis, lupus)",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "requires chronic immunosuppressive therapy, [e.g., cyclosporine A, tacrolimus]",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "chronic requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of organ transplant",
                    "criterion": "organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known bleeding disorders (von Willebrand's disease or hemophilia)",
            "criterions": [
                {
                    "exact_snippets": "Known bleeding disorders (von Willebrand's disease or hemophilia)",
                    "criterion": "bleeding disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "von Willebrand's disease",
                    "criterion": "von Willebrand's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemophilia",
                    "criterion": "hemophilia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome =< 6 months prior to pre-randomization",
            "criterions": [
                {
                    "exact_snippets": "Currently active, clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "currently active"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "history of myocardial infarction ... =< 6 months prior to pre-randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... unstable angina ... =< 6 months prior to pre-randomization",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... acute coronary syndrome =< 6 months prior to pre-randomization",
                    "criterion": "acute coronary syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other active malignancy =< 3 years prior to pre-registration; note: if there is a history of prior malignancy, the patient must not be receiving other specific treatment for cancer",
            "criterions": [
                {
                    "exact_snippets": "Other active malignancy =< 3 years prior to pre-registration",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if there is a history of prior malignancy, the patient must not be receiving other specific treatment for cancer",
                    "criterion": "receiving other specific treatment for cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "history of prior malignancy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Require continuous treatment with a strong CYP3A inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Require continuous treatment with a strong CYP3A inhibitor",
                    "criterion": "treatment with a strong CYP3A inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "continuity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastrointestinal disease that might inhibit ibrutinib absorption (e.g., malabsorption syndrome, resection of the stomach or a large portion of small bowel, or partial/complete bowel obstruction), or unable to swallow capsules",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disease that might inhibit ibrutinib absorption (e.g., malabsorption syndrome, resection of the stomach or a large portion of small bowel, or partial/complete bowel obstruction)",
                    "criterion": "gastrointestinal disease that might inhibit ibrutinib absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
            "criterions": [
                {
                    "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study",
                    "criterion": "co-morbid systemic illnesses or other severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "investigator judgment of appropriateness for study entry",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease which ... would ... interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
                    "criterion": "co-morbid systemic illnesses or other severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "interference with assessment of safety and toxicity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following",
                    "criterion": "unspecified criterion (list to follow)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Patients with untreated brain metastasis will be excluded; patients with previously treated brain metastases may participate provided they meet the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Patients with untreated brain metastasis will be excluded",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with previously treated brain metastases may participate provided they meet the following criteria",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "previously treated"
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently participating or has participated in a study of an investigational cancer therapy agent or using an investigational device within 28 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Currently participating or has participated in a study of an investigational cancer therapy agent",
                    "criterion": "participation in a study of an investigational cancer therapy agent",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to study registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "using an investigational device within 28 days prior to study registration",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to study registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody [mAb]) =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody [mAb]) =< 28 days prior to registration",
                    "criterion": "prior cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of ischemic stroke or intracranial hemorrhage =< 180 days prior to pre-registration",
            "criterions": [
                {
                    "exact_snippets": "History of ischemic stroke ... =< 180 days prior to pre-registration",
                    "criterion": "ischemic stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intracranial hemorrhage =< 180 days prior to pre-registration",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix",
            "criterions": [
                {
                    "exact_snippets": "Non-melanotic skin cancer",
                    "criterion": "skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "non-melanotic"
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinoma-in-situ of the cervix",
                    "criterion": "carcinoma-in-situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Failure to confirm histologically or cytologically unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy",
            "criterions": [
                {
                    "exact_snippets": "Failure to confirm histologically or cytologically unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy",
                    "criterion": "melanoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable stage III",
                                "metastatic melanoma (stage IV)"
                            ]
                        },
                        {
                            "requirement_type": "amenability to local therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent systemic immunosuppressant therapy =< 21 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Concurrent systemic immunosuppressant therapy =< 21 days prior to registration",
                    "criterion": "systemic immunosuppressant therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration prior to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent infection requiring systemic antibiotic treatment that was completed =< 14 prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Recent infection requiring systemic antibiotic treatment that was completed =< 14 prior to registration",
                    "criterion": "recent infection requiring systemic antibiotic treatment",
                    "requirements": [
                        {
                            "requirement_type": "completion time prior to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current use of warfarin or other vitamin K antagonists",
            "criterions": [
                {
                    "exact_snippets": "Current use of warfarin",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current use of ... other vitamin K antagonists",
                    "criterion": "vitamin K antagonist use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a strong cytochrome P450 (CYP) 3A inhibitor =< 7 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Received a strong cytochrome P450 (CYP) 3A inhibitor =< 7 days prior to registration",
                    "criterion": "receipt of strong CYP3A inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "strength",
                            "expected_value": "strong"
                        },
                        {
                            "requirement_type": "enzyme target",
                            "expected_value": "CYP3A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Live vaccines within 28 days prior to study pre-registration",
            "criterions": [
                {
                    "exact_snippets": "Live vaccines within 28 days prior to study pre-registration",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "administration prior to",
                            "expected_value": "study pre-registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with ibrutinib or prior exposure to BTK inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with ibrutinib",
                    "criterion": "ibrutinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior exposure to BTK inhibitors",
                    "criterion": "BTK inhibitor exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Invasive surgical procedure within 28 days prior to study pre-registration",
            "criterions": [
                {
                    "exact_snippets": "Invasive surgical procedure within 28 days prior to study pre-registration",
                    "criterion": "invasive surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to study pre-registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome within =< 180 days prior to registration, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification",
            "criterions": [
                {
                    "exact_snippets": "unstable angina ... within =< 180 days prior to registration",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... within =< 180 days prior to registration",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "acute coronary syndrome within =< 180 days prior to registration",
                    "criterion": "acute coronary syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic or uncontrolled arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification",
                    "criterion": "cardiac disease (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active central nervous system metastases and/or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "Active central nervous system metastases",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* On =< 10 mg/day prednisone or equivalent for at least 28 days prior pre-registration",
            "criterions": [
                {
                    "exact_snippets": "On =< 10 mg/day prednisone or equivalent for at least 28 days prior pre-registration",
                    "criterion": "prednisone or equivalent corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to pre-registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uveal melanoma",
            "criterions": [
                {
                    "exact_snippets": "Uveal melanoma",
                    "criterion": "uveal melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men or women of childbearing potential who are unwilling to employ adequate contraception within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication; adequate contraception is defined as 2 methods of birth control (e.g., hormonal contraceptives, intrauterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide) or prior surgical sterilization, or abstinence from heterosexual activity",
            "criterions": [
                {
                    "exact_snippets": "Men or women of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to employ adequate contraception within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "screening visit"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 120,
                                        "unit": "days after the last dose of study medication"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate contraception is defined as 2 methods of birth control (e.g., hormonal contraceptives, intrauterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide) or prior surgical sterilization, or abstinence from heterosexual activity",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        },
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "hormonal contraceptives",
                                "intrauterine device",
                                "diaphragm with spermicide",
                                "cervical cap with spermicide",
                                "male condoms",
                                "female condom with spermicide",
                                "prior surgical sterilization",
                                "abstinence from heterosexual activity"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently active, clinically significant hepatic impairment Child-Pugh class A, B or C according to the Child Pugh classification",
            "criterions": [
                {
                    "exact_snippets": "Currently active, clinically significant hepatic impairment",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "currently active"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Child-Pugh class A, B or C according to the Child Pugh classification",
                    "criterion": "Child-Pugh class",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "A",
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as >= 1.0 cm with computed tomography [CT] scan, CT component of a positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI]) or at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is >= 1.5 cm when assessed by CT scan)",
            "criterions": [
                {
                    "exact_snippets": "at least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as >= 1.0 cm with computed tomography [CT] scan, CT component of a positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI])",
                    "criterion": "non-nodal lesion",
                    "requirements": [
                        {
                            "requirement_type": "measurability_by_RECIST",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "longest_diameter",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "imaging_modality",
                            "expected_value": [
                                "CT",
                                "PET/CT (CT component)",
                                "MRI"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is >= 1.5 cm when assessed by CT scan)",
                    "criterion": "malignant lymph node",
                    "requirements": [
                        {
                            "requirement_type": "measurability_by_RECIST",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "short_axis",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "imaging_modality",
                            "expected_value": "CT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION- INCLUSION CRITERIA",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "* REGISTRATION- EXCLUSION",
            "criterions": []
        },
        {
            "line": "* PRE-REGISTRATION EXCLUSION CRITERIA",
            "criterions": []
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection with hepatitis B virus",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection with hepatitis C virus",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "any uncontrolled active systemic infection",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}